Skip to content
ClinCalc Pro
Menu
Antimotility opioid Pregnancy: It is not advisable to administer loperamide in pregnancy; women who are pregnant or breast-feeding should be advised to consult their doctor for appropriate treatment. Although there is no indication of teratogenic or embryotoxic properties, it should not be administered in pregnancy, especially during the first trimester. Small amounts may appear in human breast milk, so it is not recommended during breast-feeding. The effect on human fertility has not been evaluated.

Loperamide hydrochloride

Brand names: Imodium

Loperamide hydrochloride is an antimotility agent used for the symptomatic relief of acute and chronic diarrhoea.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Acute diarrhoea (adults and children 12 years and over): initial dose 4 mg (2 x 2 mg capsules), followed by 2 mg (1 capsule) after every subsequent loose stool. The usual dose is 6 mg to 8 mg (3 to 4 capsules) a day
Route: Oral - capsules should be taken with liquid
Frequency: 4 mg initially, then 2 mg after each subsequent loose stool
Max: 12 mg (6 capsules) daily - the maximum daily dose should not exceed 6 capsules (12 mg)
SOURCE SCOPE: the SPC fetched is 'Boots Diarrhoea Relief 2 mg Capsules (P and GSL)', an over-the-counter product; the pharmacy/GSL indications and duration limits below reflect that. Second indication - symptomatic treatment of acute episodes of diarrhoea associated with irritable bowel syndrome in adults aged 18 years and over, following initial diagnosis by a doctor: 4 mg (two capsules) initially, followed by 2 mg (one capsule) after every loose stool, or as previously advised by the doctor; maximum daily dose must not exceed 12 mg (6 capsules); the patient should consult their doctor if new symptoms develop, if symptoms worsen, or if symptoms have not improved over two weeks. Duration: in acute diarrhoea, if symptoms persist for more than 24 hours consult a doctor, and if clinical improvement is not observed within 48 hours loperamide should be discontinued and the patient advised to consult their physician, since persistent diarrhoea can indicate a more serious condition. Should not be used for prolonged periods until an underlying cause for persistent diarrhoea has been investigated and diagnosed by a doctor. Fluid and electrolyte replacement is the most important measure in patients with diarrhoea, especially children and frail or elderly patients. Children under 12 years: loperamide capsules should not be used (also listed as a contraindication) - consult a children's formulary. Elderly: no dose adjustment required. Renal impairment: no dose adjustment required. Hepatic impairment: no pharmacokinetic data available, but use with caution because of reduced first-pass metabolism, which may result in a relative overdose leading to CNS toxicity. Cardiac events including QT interval and QRS complex prolongation and torsade de pointes have been reported in association with overdose, some with a fatal outcome, and overdose can unmask existing Brugada syndrome - patients should not exceed the recommended dose or duration of treatment. Caution in patients with a history of drug abuse; abuse and misuse of loperamide have been described. Patients with AIDS treated for diarrhoea should have therapy stopped at the earliest signs of abdominal distension. Contains lactose monohydrate and Ponceau 4R (E124), which can cause allergic-type reactions including asthma.

Dose adjustments

Renal

No dose adjustment is required for patients with renal impairment.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Known hypersensitivity to loperamide hydrochloride or to any of the excipients
  • Children under 12 years of age
  • Acute dysentery, characterised by blood in stools and high fever
  • Acute ulcerative colitis
  • Bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella and Campylobacter
  • Pseudomembranous colitis associated with the use of broad-spectrum antibiotics
  • Should not be used when inhibition of peristalsis is to be avoided, due to the possible risk of significant sequelae including ileus, megacolon and toxic megacolon; must be discontinued promptly if constipation, abdominal distension or ileus develop

Side effects

  • Constipation (2.7%) - common
  • Flatulence (1.7%), nausea, abdominal pain, abdominal discomfort, dry mouth - common
  • Headache (1.2%) - common; dizziness - uncommon
  • Rash - uncommon; bullous eruption including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme, angioedema, urticaria, pruritus - post-marketing
  • Ileus (including paralytic ileus), megacolon including toxic megacolon, abdominal distension, acute pancreatitis - rare/post-marketing; hypersensitivity and anaphylactic reactions including anaphylactic shock - post-marketing

Clinical monograph

How it works

It is a peripherally acting opioid receptor agonist in the gut wall that slows intestinal motility and increases transit time, allowing greater absorption of fluid and electrolytes, with negligible central effects at normal doses.

Prescribing in practice

  • Avoid in acute diarrhoea where reducing motility is hazardous, including suspected bacterial colitis, dysentery with blood and fever, and active ulcerative colitis flares where it can precipitate toxic megacolon.
  • Serious cardiac events including QT prolongation and arrhythmia have been reported with overdose, so it must not be exceeded and is liable to misuse.
  • It should not be used as the sole treatment in young children and is not a substitute for rehydration in infective diarrhoea.

Monitoring

No routine monitoring is required for short-term use; review if diarrhoea persists, worsens, or is accompanied by blood, fever or abdominal distension.

Counselling the patient

  • Take plenty of fluids to replace what is lost; this medicine treats the symptom but not the cause.
  • Stop and seek advice if you develop a high fever, blood in the stool, or marked abdominal swelling, and never exceed the stated dose.

Evidence & guidelines

Loperamide is a widely established first-line antimotility treatment for symptomatic relief of uncomplicated diarrhoea.

Reference: NICE CKS; MHRA Drug Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.